Aromatic L-amino acid decarboxylase (AAAD) activity in rhesus macaque striatum after MAO-B inhibition by Ro 16-6491

Synapse

Volumn 56, Issue 1, 2005, Pages 54-56

  Dejesus, O T ^a   Flores, L G ^a   Roberts, A D ^a   Dick, D W ^a   Bartlett, R M ^a   Murali, D ^a   Nickles, R J ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AROMATIC LEVO AMINO ACID DECARBOXYLASE; N (2 AMINOETHYL) 4 CHLOROBENZAMIDE;

ARTICLE; CORPUS STRIATUM; DEAMINATION; DOPAMINE METABOLISM; DOWN REGULATION; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME REGULATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RHESUS MONKEY;

ANIMALS; AROMATIC-L-AMINO-ACID DECARBOXYLASES; BENZAMIDES; CORPUS STRIATUM; ENZYME ACTIVATION; MACACA MULATTA; MALE; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; TYROSINE;

EID: 14644408023     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.20119     Document Type: Article

References (12)

1. Cho S, Duchemin AM, Neff NH, Hadjiconstantinou M. 1996 Modulation of tyrosine hydroxylase and aromatic L-amino acid decarboxylase after inhibiting monoamine oxidase-A. Eur J Pharmacol 314:51-59.
2. Cho S, Neff NH, Hadjiconstantinou M. 1997. Regulation of tyrosine hydroxylase and aromatic L-amino acid decarboxylase by dopaminergic drugs. Eur J Pharmacol 323:149-157.
3. DaPrada M, Kettler R, Keller HH, Cesura AM, Richards JG, Saura Marti J, Muggli-Maniglio D, Wyss PC, Kyburz E, Imhof R. 1990. From moclobemide to Ro 19-6327 and Ro 41-1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors. J Neural Transm Suppl 29:279-292.
4. DeJesus OT, Endres CJ, Shelton SE, Nickles RJ, Holden JE. 1997. Evaluation of fluorinated m-tyrosine analogs as PET imaging agents of dopamine nerve terminals: comparison with 6-fluoro-DOPA. J Nucl Med 38:630-636.
5. 18F]fluoro-m-tyrosine, an aromatic 1-amino acid decarboxylase tracer. J Label Comp Radiopharm 42(Suppl 1):S392-S394.
6. DeJesus OT, Endres CJ, Shelton SE, Nickles RJ, Holden JE. 2001. Noninvasive assessment of aromatic 1-amino acid decarboxylase activity in aging rhesus monkey brain in vivo. Synapse 39:58-63.
7. 18F]L-DOPA. Eur J Pharmacol 334:31-38.
8. Kaseda S, Nomoto M, Iwata S. 1999. Effect of selegiline on dopamine concentration in the striatum of a primate. Brain Res 815:44-50.
9. Kinemuchi H, Fowler CJ, Tipton KF. 1984. Substrate specificities of the two forms of monoamine oxidase. In: Tipton KF, Dostert P, Strolin Benedetti M, editors. Monoamine oxidase and disease: prospects for therapy with reversible inhibitors. London: Academic Press. p 53-62.
10. Lamensdorf I, Finberg JP. 1997. Reduced striatal tyrosine hydroxylase activity is not accompanied by change in responsiveness of dopaminergic receptors following chronic treatment with deprenyl. Neuropharmacology 36:1455-1461.
11. Napolitano A, Cesura AM, Da Prada M. 1995. The role of monoamine oxidase and catechol-O-methyltransferase in dopaminergic neurotransmission. J Neural Transm Suppl 45:35-45.
12. Paterson IA, Davis BA, Durden DA, Juorio AV, Yu PH, Ivy G, Milgram W, Mendonca A, Wu P, Boulton AA. 1995. Inhibition of MAO-B by (-)-deprenyl alters dopamine metabolism in the macaque (Macaca facicularis) brain. Neurochem Res 20:1503-1510.